Clinical Trial Update: Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating phosphatidylserine enriched with omega-3 fatty acids for ADHD symptoms in children with epilepsy. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Epilepsy

Drugs mentioned

• Phosphatidylserine enriched with omega-3 fatty acids (phosphatidylserine with omega-3 polyunsaturated fatty acids)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Attention Deficit Disorder With Hyperactivity, ADHD Inattention or Mixed Type | Phase 3 | Status: COMPLETED